Researchmoz added Most up-to-date research on "Competitor Analysis Of Inhibitory And Stimulatory Immunomodulators In Immuno-Oncology" to its huge collection of research reports.
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies.
Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:
Negative Immune Checkpoints:
PD-1(programmed cell death 1
PD-L1(programmed cell death ligand 1 (PD-L1)
(Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
(Lymphocyte Activation Gene 3; CD223)
(T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
(V-region Ig-containing Suppressor of T-cell Activation) Receptor
(Carcino-Embryonic Antigen Cell Adhesion Molecule 1)
BTLA (B- and T-Lymphocyte Attenuator)
GARP (Glycoprotein A Repetitions Predominant)
TIGIT(T-cell Immunoreceptor with Ig and ITIM domains)
IL-10(Interleukin-10)
B7-H3(CD273)
Stimulatory Immune Checkpoints:
CD40 (TNFSFR5)
GITR(Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
OX40(CD134; TNFSFR4)
4-1BB(CD137; TNFSFR9)
CD27 (TNFSFR7)
ICOS(Inducible Co-Stimulator)
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=895857
Immunosuppressive tumor microenvironment:
IDO (Indoleamine 2,3-dioxygenase
TDO ( Tryptophan 2,3 dioxygenase)
TGF-B/R ( Transforming Growth Factor beta/Receptor)
CXCR4 (Chemokine Receptor Type 4)
CSF-1R ( Colony Stimulating Factor-1 Receptor)
CD47 SIRPa (Signal Regulatory Protein Alpha)
Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
STING (STimulator of INterferon Genes) Receptor
Others ( e.g. arginase)
More than 90 unique molecules (mostly antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further 31 molecules are undergoing IND-enabling studies.
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=895857
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies.
Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:
Negative Immune Checkpoints:
PD-1(programmed cell death 1
PD-L1(programmed cell death ligand 1 (PD-L1)
(Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
(Lymphocyte Activation Gene 3; CD223)
(T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
(V-region Ig-containing Suppressor of T-cell Activation) Receptor
(Carcino-Embryonic Antigen Cell Adhesion Molecule 1)
BTLA (B- and T-Lymphocyte Attenuator)
GARP (Glycoprotein A Repetitions Predominant)
TIGIT(T-cell Immunoreceptor with Ig and ITIM domains)
IL-10(Interleukin-10)
B7-H3(CD273)
Stimulatory Immune Checkpoints:
CD40 (TNFSFR5)
GITR(Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
OX40(CD134; TNFSFR4)
4-1BB(CD137; TNFSFR9)
CD27 (TNFSFR7)
ICOS(Inducible Co-Stimulator)
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=895857
Immunosuppressive tumor microenvironment:
IDO (Indoleamine 2,3-dioxygenase
TDO ( Tryptophan 2,3 dioxygenase)
TGF-B/R ( Transforming Growth Factor beta/Receptor)
CXCR4 (Chemokine Receptor Type 4)
CSF-1R ( Colony Stimulating Factor-1 Receptor)
CD47 SIRPa (Signal Regulatory Protein Alpha)
Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
STING (STimulator of INterferon Genes) Receptor
Others ( e.g. arginase)
More than 90 unique molecules (mostly antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further 31 molecules are undergoing IND-enabling studies.
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=895857
No comments:
Post a Comment